Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sorrento Therapeutics Inc
(NQ:
SRNE
)
0.3073
UNCHANGED
Last Price
Updated: 4:00 PM EST, Feb 22, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Sorrento Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Sorrento Reports Encouraging Data From Sofusa-Administered Enbrel In Rheumatoid Arthritis
May 20, 2021
Sorrento Therapeutics Inc (NASDAQ: SRNE) reported positive initial results from the Phase 1B study of its Sofusa Lymphatic Delivery System administering Amgen...
Via
Benzinga
Market Briefing For Thursday, May 6
May 06, 2021
Wednesday was fairly stock specific (Peleton etc.), as well pharma, as the White House decided to vanquish vaccine IP rights, slapping those stocks counting on years-long revenue streams. Oils and...
Via
Talk Markets
Market Briefing For Wednesday, May 5
May 05, 2021
Janet Yellen said 'interest rates may need to rise moderately', and that's a part of the backdrop, though S&P has been set-up for decline for awhile.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Market Briefing For Wednesday, Apr. 28
April 28, 2021
Tactical behavior requires no change whatsoever. Just recognize that signs of an impending 'big-cap' correction are rising, with less erosion probably in a slew of small-cap stocks that have already...
Via
Talk Markets
Sorrento To Start Testing STI-3031 In Patients With Advanced Urothelial Carcinoma
April 27, 2021
The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ: SRNE) IND to proceed with a Phase 2a study for STI-3031 for advanced urothelial carcinoma. STI...
Via
Benzinga
Exposures
Product Safety
Why Sorrento Therapeutics' Stock Is Trading Higher Today
April 27, 2021
Sorrento Therapeutics (NASDAQ: SRNE) shares are trading higher after the company received FDA clearance to proceed with its Phase 2 study for Sti-3031 in advanced urothelial...
Via
Benzinga
Exposures
Product Safety
Why Sorrento Therapeutics Stock Is Soaring Today
April 26, 2021
Hint: It's not because of anything the company said or did.
Via
The Motley Fool
Cramer Shares His Thoughts On Ferrari, Palantir And More
April 26, 2021
On CNBC's "Mad Money Lightning Round," Jim Cramer said Ferrari N.V. (NYSE: RACE) is just fabulous. He is a buyer of the stock. Cramer wouldn't hang around...
Via
Benzinga
Market Briefing For Monday, Apr. 26
April 26, 2021
Nasdaq is perking up, primarily led by FANG types reporting next week (discounted). So, higher a bit near-term; then, risks.
Via
Talk Markets
Sorrento's Human Derived Mesenchymal Stem Cells Achieves 100% Discharge Rate In Critically-Ill COVID-19 Patients
April 20, 2021
Sorrento Therapeutics Inc (NASDAQ: SRNE) has announced data from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC)...
Via
Benzinga
Exposures
COVID-19
Market Briefing For Monday, April 19
April 18, 2021
Next week should see consolidation and upside, and then correction risk rises. We're cautious and looking for a setback, but not catastrophe ahead.
Via
Talk Markets
Sorrento Therapeutics Stock Looks To Form Bullish Falling Wedge
April 12, 2021
Sorrento Therapeutics Inc. (NASDAQ: SRNE) shares lost ground Monday with no evident explanation. The stock was trending on StockTwits. Sorrento Therapeutics was down 7....
Via
Benzinga
Week In Review: Sorrento Acquires ACEA In $488 Million Deal Between Two San Diego-China Oncology Biopharmas
April 10, 2021
Sorrento Therapeutics will acquire ACEA Therapeutics in a deal worth up to $488 million. Both companies develop novel cancer drugs, both are headquartered in San Diego and both have operations in...
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.